登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Safety and Dystrophin Expression of SPOT-03 in Duchenne Muscular Dystrophy (DMD) Patients
ClinicalTrials.gov 上登记的一项杜氏肌营养不良开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月13日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07188012,读取于 2026年11月13日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
2 岁 至 7 岁;性别:仅男性
登记记录的入选字段
Able to tolerate muscle biopsy under anesthesia and have no contraindications to biopsy.
入选标准第 4 条
Subjects with a history of major surgeries within 12 weeks prior to the initial infusion or planning to undergo major surgeries (such as scoliosis surgery) during this study.
排除标准第 17 条
Within 6 months prior to the initial infusion, the subjects are exposed to another investigational drug or have participated in an intervention clinical trial.
排除标准第 19 条
Bilirubin ≥ 3.0 mg/dL
排除标准第 10 条
Creatinine ≥ 1.8 mg/dL
排除标准第 11 条
Hemoglobin < 8 or > 18 g/dL
排除标准第 12 条
Subjects with positive hepatitis B core antibody or hepatitis C antibody or HIV antibody during screening.
排除标准第 20 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);日常活动能力;影像与可测量病灶;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07188012,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
According to the requirements of the region/country and/or IRB/IEC, the patient and/or legal guardian have signed a written informed consent form and are aware of all relevant study content. Boys aged ≥ 2 years to < 8 years and capable of walking independently for at least 10 meters. The medical history includes clinical diagnosis of DMD and confirmed Duchenne mutations using validated genetic testing (MLPA and whole genome sequencing). Able to tolerate muscle biopsy under anesthesia and have no contraindications to biopsy. Heart, liver, lung, and kidney functions are sufficient: The left ventricular ejection fraction (LVEF) should be ≥ 50%; Forced vital capacity (FVC) > 50% of the expected value, and do not require nighttime ventilation; Patient's glomerular filtration rate (GFR)>30 mL/min/1.73 m2排除标准:Exclusion Criteria:
Complications other than DMD that may cause muscle weakness and/or motor dysfunction. There are severe intellectual disabilities (such as severe autism, severe cognitive impairment, and severe behavioral disorders) that, according to the investigator's judgment, can affect the study. Hospitalization for respiratory failure within 8 weeks prior to screening. Asthma or underlying lung diseases that are poorly controlled, such as bronchitis, bronchiectasis, emphysema, or recurrent infectious pneumonia that investigator believes may affect respiratory function. Severe uncontrolled heart failure (NYHA III-IV), including any of the following conditions: Intravenous administration of diuretics or positive inotropic drugs is required within 8 weeks prior to screening. Hospitalization due to worsening heart failure or arrhythmia within 8 weeks prior to screening. Abnormal laboratory values considered clinically significant: GGT > 3 × upper limit of normal Bilirubin ≥ 3.0 mg/dL Creatinine ≥ 1.8 mg/dL Hemoglobin < 8 or > 18 g/dL White blood cell count > 18,500/μL Arrhythmias that require anti-arrhythmic treatment. Subjects who are undergoing immunosuppressive therapy. Has used other gene therapy, investigational drugs, or any treatment aimed at increasing dystrophin expression. Subjects with a history of major surgeries within 12 weeks prior to the initial infusion or planning to undergo major surgeries (such as scoliosis surgery) during this study. Subjects who are allergic to investigational products or local aesthetic drugs or have a history of severe allergies or genetic allergic reactions. Within 6 months prior to the initial infusion, the subjects are exposed to another investigational drug or have participated in an intervention clinical trial. Subjects with positive hepatitis B core antibody or hepatitis C antibody or HIV antibody during screening. Investigator believes that the presence of any other serious diseases, medical conditions, or chronic drug treatment needs can pose unnecessary risks to gene transfer.
引自 ClinicalTrials.gov, NCT07188012, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07188012,读取于 2026年11月13日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。